Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

DNSSEC

Google

Google Cloud

Facebook Sharer

Microsoft

AWS Global Accelerator

Amazon Route 53

Microsoft Azure

Google Cloud Global Multi-Region

Mailgun

Global Head, Human Resources, CHRO

Debra Canner

Finance and Administration

Jim Frates

Co-CEO and Co-Founder

Joshua Cohen

Co-Founder & Co-CEO

Justin Klee

Chief Scientific Officer at Amylyx Pharmaceuticals

Kent Leslie

Global Head of Clinical R&D & CMO

Patrick Yeramian

Head of Marketing Operations

Jacci Lufkin, HMCC

Vice President, Head Global Medical Affairs

Machelle Manuel

VP, Head of Global Compliance & Legal

Sue Dyer

Regional Business Director

Aaron Felix

Steve Chubb

George M. Milne

President and Founder

CEO and Founder

Gina M. Mazzariello

Chief Legal Officer & General Counsel

Camille Bedrosian

Chief Medical Officer

Chief Financial Officer

Timothy Lee

2nd Commercial Member - Pre IPO - Pre Commercialization

Perceptive Advisors Portfolio Companies

New England Public Companies With More Than $1M in Revenue

Northeastern US Companies With Fewer Than 1000 Employees (Top 10K)

United States Public Companies With More Than $50M in Revenue

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration.

Post-IPO Equity - Amylyx Pharmaceuticals

Viking Global Investors

Series C - Amylyx Pharmaceuticals

Series B - Amylyx Pharmaceuticals

Debt Financing - Amylyx Pharmaceuticals

Series A - Amylyx Pharmaceuticals

Seed Round - Amylyx Pharmaceuticals

Cambridge

Massachusetts

United States

North America

Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Amylyx seeks to fill Relyvrio-sized hole in pipeline with $35M GLP-1 buy

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

Amylyx Pharmaceuticals Reports Q1 2024 Financial Results

Maker of ALS drug pulls Relyvrio off the market, keeping a promise to patients : Shots - Health News

Lots of drug companies talk about putting patients first — but this one actually did

Germany

Europe

Spain

Canada

Nepal

Asia

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	5c6c23dc
crunchbase profile	general	Oct 29, 2024 5:26 PM	d3586e60
li profile	general	Jan 26, 2024 5:07 PM	54604d05
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	048bb03d
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

140.77M

Beta: -

Volume Today

831.95K

Avg: -